Results 271 to 280 of about 114,065 (338)

Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation. [PDF]

Br J Haematol
Perutelli F, Boccellato E, Montalbano MC, Catania G, Deodato M, Frustaci AM, Innocenti I, Moia R, Quaglia FM, Quaresmini G, Rivela P, Gaidano G, Krampera M, Laurenti L, Rambaldi A, Bruno B, Vitale C, Coscia M.   +17 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Chronic lymphocytic leukaemia

The Lancet, 2018
Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is ...
Michael, Hallek, Tait D, Shanafelt, Barbara, Eichhorst   +2 more
semanticscholar   +5 more sources

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.

Lancet, The, 2023
BACKGROUND Patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma for whom treatment has failed with both Bruton tyrosine kinase (BTK) inhibitor and venetoclax have few treatment options and poor outcomes.
T. Siddiqi, D. Maloney, S. Kenderian, D. Brander, K. Dorritie, J. Soumerai, P. Riedell, N. Shah, R. Nath, B. Fakhri, D. Stephens, Shuo Ma, T. Feldman, S. Solomon, S. Schuster, S. Perna, S. Tuazon, S. Ou, E. Papp, Leanne Peiser, Yizhe Chen, W. Wierda   +21 more
semanticscholar   +3 more sources

Chronic lymphocytic leukaemia

The Lancet, 2008
Chronic lymphocytic leukaemia is the commonest form of leukaemia in Europe and North America, and mainly, though not exclusively, affects older individuals. It has a very variable course, with survival ranging from months to decades. Major progress has been made in identification of molecular and cellular markers that could predict disease progression ...
Dighiero, G., Hamblin, T.J.
openaire   +5 more sources

[Chronic lymphocytic leukaemia].

Ugeskrift for laeger, 2021
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the world with approximately 450 new cases yearly in Denmark. The disease is highly heterogeneous, and half of the patients will never require treatment. The standard treatment is chemoimmunotherapy, but highly effective targeted therapies are approved for patients with high-risk ...
Caspar, da Cunha-Bang, Christian, Brighel, Carsten Utoft, Niemann   +2 more
semanticscholar   +4 more sources

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Lancet, The, 2010
M. Hallek, K. Fischer, G. Fingerle-Rowson, A. Fink, R. Busch, J. Mayer, M. Hensel, G. Hopfinger, G. Hess, U. V. Grünhagen, Matthias Bergmann, J. Catalano, P. Zinzani, F. Caligaris‐cappio, J. Seymour, A. Berrebi, U. Jäger, B. Cazin, M. Trněný, A. Westermann, C. Wendtner, B. Eichhorst, P. Staib, A. Bühler, D. Winkler, T. Zenz, S. Böttcher, M. Ritgen, M. Mendila, M. Kneba, H. Döhner, S. Stilgenbauer   +31 more
semanticscholar   +3 more sources

Chronic lymphocytic leukaemia: from genetics to treatment

Nature Reviews Clinical Oncology, 2019
F. Bosch, R. Dalla-Favera
semanticscholar   +3 more sources

Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

The Lancet Oncology, 2023
BACKGROUND In the GLOW study, fixed-duration ibrutinib-venetoclax showed superior progression-free survival versus chlorambucil-obinutuzumab in patients with previously untreated chronic lymphocytic leukaemia who were older or had comorbidities, or both,
C. Niemann, T. Munir, C. Moreno, Carolyn Owen, G. Follows, O. Benjamini, A. Janssens, M. Levin, Tadeusz Robak, M. Šimkovič, Sergey Voloshin, V. Vorobyev, M. Yağcı, L. Ysebaert, K. Qi, Qianya Qi, Pierre Sinet, Lori Parisi, Srimathi Srinivasan, N. Schuier, K. Baeten, A. Howes, D. B. Caces, A. Kater   +23 more
semanticscholar   +1 more source

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.

The Lancet Oncology, 2022
BACKGROUND Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with efficacy in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
C. Tam, Jennifer R. Brown, B. Kahl, P. Ghia, K. Giannopoulos, W. Jurczak, M. Šimkovič, M. Shadman, A. Österborg, L. Laurenti, P. Walker, Stephen Samuel Opat, Henry Chan, H. Ciepłuch, R. Greil, M. Tani, M. Trněný, D. Brander, I. Flinn, S. Grosicki, E. Verner, A. Tedeschi, Jianyong Li, T. Tian, Lei Zhou, Carol Marimpietri, J. Paik, A. Cohen, Jane Huang, T. Robak, P. Hillmen   +30 more
semanticscholar   +1 more source